Industry News
Pharmaceutical Industry News
Point-of-care marketing promises…
Point-of-care marketing promises conversion, but many strategies miss the prescribing moment. Are these common assumptions undermining your results?
The $3 billion investment will…
The $3 billion investment will take shape over the next ten years, the company said, and will increase the global supply of its oral GLP-1 prospect orforglipron.
After strutting its stuff against…
After strutting its stuff against blockbusters in three head-to-head psoriasis trials, UCB’s Bimzelx has conquered another powerhouse product—AbbVie’s Skyrizi—in psoriatic arthritis in a head-to-head phase 3b study.
Johnson & Johnson CEO Joaquin…
Johnson & Johnson CEO Joaquin Duato has been awarded nearly $32.8 million in 2025 pay, marking a significant leap over the $24.3 million he was granted for 2024.
Skyhawk Therapeutics has named…
Skyhawk Therapeutics has named Aaron Deves as chief commercial officer, securing the expertise of an executive who oversaw products including Austedo while at Teva. The company shared the news the same day Santhera Pharmaceuticals revealed
Biopharma companies are signaling…
Biopharma companies are signaling a tougher year ahead. As patent protections expire and growth slows across the industry, only a handful of drugmakers expect bigger gains in 2026.
Sandoz is committing even further…
Sandoz is committing even further to its biosimilar business with plans to launch a dedicated unit that will operate separately from the company’s remaining small molecule generics division.
In his second year as CEO,…
In his second year as CEO, AbbVie's Robert Michael received a $32.5 million pay package, a hefty raise from his 2024 pay of $18.5 million.
Pharmas’ direct drug sale…
Pharmas’ direct drug sale platforms could be the key to bridging the sizable gap between patients’ awareness of certain medications and actual prescription numbers, a new survey suggests.
Leerink Partners called the…
Leerink Partners called the departure of BioNTech CEO Uğur Şahin and his wife, and CMO Özlem Türeci, to establish a new startup a "logical step." But the analysts also questioned whether the German company can
Amid the company’s efforts to…
Amid the company’s efforts to resolve issues raised during an FDA inspection early last year, Novo Nordisk’s operating base in Plainsboro, New Jersey—already the recipient of a recent Form 483—has been hit with the more
Cassava Sciences has rebranded as…
Cassava Sciences has rebranded as Filana Therapeutics, shedding the baggage associated with the old name as the biotech plants itself in a new therapeutic area.
Monday, CSL broke ground on an…
Monday, CSL broke ground on an expansion at its Kankakee, Illinois, facility, a move set to substantially bolster the company’s production capacity for plasma-derived therapy.
About five months after U.S….
About five months after U.S. Health Secretary Robert F. Kennedy Jr. touted leucovorin as “an exciting therapy that may benefit large numbers of children who suffer from autism” during a White House press conference, the
After nearly nine years as GSK’s…
After nearly nine years as GSK’s CEO, Emma Walmsley exited on a high note as her total compensation for 2025 surged nearly 50% to 15.7 million pounds sterling ($21 million).
The FDA’s newest draft guidance…
The FDA's newest draft guidance reinforces its previous commitment to streamlining biosimilar drug development by removing certain testing requirements for the cheaper biologic drugs.
With sales booming at Eli Lilly,…
With sales booming at Eli Lilly, the Indianapolis company has compensated CEO David Ricks with a $36.7 million pay package in 2025, which is up from $29.2 million in 2024.
Spruce Biosciences has named Dale…
Spruce Biosciences has named Dale Hooks as chief commercial officer, securing a leader with experience launching 21 products as the company heads toward a filing for its first FDA approval.
The agreement marks the end of a…
The agreement marks the end of a longstanding public feud and allows Hims & Hers to sell Novo's branded Ozempic and Wegovy on its telehealth platform.
With a new FDA nod in hand for…
With a new FDA nod in hand for Sotyktu as a treatment for adults with active psoriatic arthritis, Bristol Myers Squibb can reach more patients with the oral TYK2 inhibitor.